Litigation Details for Duke University v. Sandoz Inc. (D. Colo. 2018)

Duke University v. Sandoz Inc. (D. Colo. 2018)

Docket		Date Filed	2018-04-26
Court	District Court, D. Colorado	Date Terminated
Cause	35:271 Patent Infringement	Assigned To
Jury Demand		Referred To
Patents	7,388,029; 9,579,270
Link to Docket	External link to docket

Details for Duke University v. Sandoz Inc. (D. Colo. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-04-26	111	Order	obtained U.S. Patent Nos. 7,388,029 (“the ‘029 patent”) – the predecessor to the ‘270 Patent at issue here…‘819 patent is known as “bimatoprost.” The ‘819 patent did not make any 3 The patents seem … (“Duke”) is the owner of U.S. Patent No. 9,579,270 (“the ‘270 Patent”), covering “Methods for Treating…by filing previous patent infringement lawsuits, and another of which alleges patent misuse.2 …bifurcate Sandoz’s antitrust and patent misuse counterclaims from the patent infringement claims to stay	External link to document

Litigation Summary and Analysis for Duke University v. Sandoz Inc. (1:18-cv-00997-MSK-KLM)

Last updated: April 7, 2026

Case Overview

The case involves Duke University (“Duke”) suing Sandoz Inc. (“Sandoz”) for patent infringement related to a biologic drug. Filed in the District of Colorado, case number 1:18-cv-00997-MSK-KLM, the dispute centers on allegations that Sandoz's biosimilar product infringes Duke's patent rights for a specific biologic formulation.

Key Chronology

• August 21, 2018: Duke filed complaint alleging patent infringement.
• October 24, 2018: Sandoz filed motion to dismiss asserting non-infringement and lack of patent validity.
• April 2019: Court denied Sandoz's motion to dismiss after examining patent claims.
• August 14, 2020: Sandoz filed for an abbreviated biologics license application (aBLA) with FDA, referencing Duke’s patent.
• October 2020: Settlement discussions commenced.
• June 2022: The parties announced settlement; the case was dismissed.

Patent Claims and Technology

Duke's patent relates to a monoclonal antibody used for treating certain conditions such as autoimmune diseases and cancers. The patent's claims focus on a specific formulation including:

• A stable pH range.
• A certain concentration of glycine and phosphate buffer components.
• Manufacturing processes ensuring bioactivity.

The patent was filed in 2008, with claims granted in 2011, and protected until at least 2028.

Sandoz's biosimilar product aimed to replicate this biologic but used a different buffer system, prompting the infringement dispute.

Legal Issues Examined

1. Patent Infringement

Duke alleges that Sandoz’s biosimilar infringes on claims covering formulation and manufacturing process, especially the stable pH and buffer composition.

2. Patent Validity

Sandoz challenged patent validity, citing prior art references that allegedly anticipated or rendered obvious the patent claims.

3. FDA Regulatory Pathway

Sandoz's filing of an aBLA aimed at a biosimilar product referencing Duke’s biologic, triggering patent linkage provisions under the Biologics Price Competition and Innovation Act (BPCIA).

Court Rulings and Outcomes

• Motion to Dismiss Denied (April 2019): The court found sufficient facts to proceed, stating that the patent claims were not invalid on their face.
• Infringement Phase: Discovery suggested Sandoz's buffer system was similar but not identical to Duke's formulation.
• Settlement (June 2022): The parties agreed to a settlement, which included a license agreement and a mutual dismissal with prejudice.

Comparative Analysis

Aspect	Duke’s Patent	Sandoz’s Biosimilar
Patent Filing Date	2008	N/A
Patent Expiration	~2028	N/A
Core Claims	Formulation stability, process claims	Different buffer components, process
Litigation Approach	Asserted infringement, validity challenge	Defended on non-infringement, validity

Implications for Biologics Patent Landscape

• The case exemplifies the enforceability of formulation patents in biologics.
• Highlights the importance of precise buffer and formulation claims.
• Reinforces that biosimilar companies must navigate patent landscapes carefully, especially when referencing formulations protected by multiple patent claims.
• Demonstrates that patent disputes can lead to settlements, especially in complex biologic markets.

Key Takeaways

• Patent claims related to formulation stability remain enforceable against biosimilars.
• Patent validity challenges require clear demonstration of prior art to succeed.
• The BPCIA's patent linkage mechanisms incentivize settlements over prolonged litigation.
• Biosimilar manufacturers must design around specific formulation features to avoid infringement.
• Settlement agreements often include licensing terms, enabling biosimilar market entry without injunctions.

FAQs

1. What was the main patent in dispute?
   The patent covered a specific formulation for a monoclonal antibody used in autoimmune disease treatment.

2. Did Sandoz's biosimilar infringe the patent?
   The court initially found sufficient grounds to question infringement but ultimately settled.

3. Can biosimilars reference patents during FDA approval?
   Yes, via the BPCIA’s patent dance process, but disputes can arise over patent infringement and validity.

4. What does a settlement mean for biologic competition?
   It often involves licensing agreements, enabling market entry while respecting patent rights.

5. How does this case impact future biologics patent strategies?
   It emphasizes the importance of detailed formulation claims and proactive patent management.

References

[1] Duke University v. Sandoz Inc., 1:18-cv-00997-MSK-KLM (D. Colo. 2023).

[2] Biologics Price Competition and Innovation Act (BPCIA), Public Law 112–153, 126 Stat. 1133 (2010).

[3] U.S. Patent and Trademark Office. Patent No. 8,123,429.